Nevro (NVRO) Reaches $81.17 After 8.00% Down Move; 6 Bullish Analysts Covering Ignyta (RXDX)

August 10, 2017 - By Hazel Jackson

The stock of Nevro Corp (NYSE:NVRO) is a huge mover today! About 109,263 shares traded. Nevro Corp (NYSE:NVRO) has risen 14.69% since August 10, 2016 and is uptrending. It has underperformed by 2.01% the S&P500.The move comes after 9 months negative chart setup for the $2.39 billion company. It was reported on Aug, 10 by Barchart.com. We have $74.68 PT which if reached, will make NYSE:NVRO worth $191.20M less.

Among 6 analysts covering Ignyta (NASDAQ:RXDX), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ignyta had 12 analyst reports since August 12, 2015 according to SRatingsIntel. The company was initiated on Tuesday, November 10 by Cantor Fitzgerald. The rating was initiated by Canaccord Genuity on Monday, October 26 with “Buy”. Cantor Fitzgerald maintained the stock with “Buy” rating in Monday, July 10 report. The rating was initiated by Credit Suisse with “Outperform” on Thursday, January 21. The firm has “Buy” rating by Jefferies given on Friday, October 23. As per Thursday, June 23, the company rating was initiated by JP Morgan. The firm has “Buy” rating given on Monday, October 26 by Cantor Fitzgerald. Cantor Fitzgerald maintained the stock with “Buy” rating in Sunday, June 4 report. The rating was maintained by Piper Jaffray on Wednesday, August 12 with “Overweight”. The stock of Ignyta Inc (NASDAQ:RXDX) has “Outperform” rating given on Tuesday, March 15 by Credit Suisse. See Ignyta Inc (NASDAQ:RXDX) latest ratings:

10/07/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $15.0000 Maintain
04/06/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $15.0000 Maintain

Analysts await Nevro Corp (NYSE:NVRO) to report earnings on August, 14. They expect $-0.29 EPS, down 7.41% or $0.02 from last year’s $-0.27 per share. After $-0.50 actual EPS reported by Nevro Corp for the previous quarter, Wall Street now forecasts -42.00% EPS growth.

Among 13 analysts covering Nevro Corp (NYSE:NVRO), 11 have Buy rating, 1 Sell and 1 Hold. Therefore 85% are positive. Nevro Corp had 24 analyst reports since August 13, 2015 according to SRatingsIntel. JMP Securities maintained Nevro Corp (NYSE:NVRO) on Tuesday, August 9 with “Market Outperform” rating. Northland Capital maintained the shares of NVRO in report on Thursday, July 6 with “Buy” rating. The stock has “Overweight” rating by PiperJaffray on Friday, July 22. The firm has “Buy” rating by Northland Capital given on Tuesday, August 8. On Tuesday, July 19 the stock rating was initiated by William Blair with “Outperform”. The stock of Nevro Corp (NYSE:NVRO) has “Outperform” rating given on Friday, September 25 by BMO Capital Markets. BMO Capital Markets maintained Nevro Corp (NYSE:NVRO) rating on Tuesday, June 6. BMO Capital Markets has “Buy” rating and $10600 target. Northland Capital initiated Nevro Corp (NYSE:NVRO) rating on Tuesday, March 29. Northland Capital has “Market Perform” rating and $48 target. The firm earned “Buy” rating on Sunday, August 6 by Canaccord Genuity. BMO Capital Markets maintained it with “Buy” rating and $10600 target in Tuesday, July 11 report.

Nevro Corp. is a global medical device company. The company has market cap of $2.39 billion. The Firm focuses on providing products that improve the quality of life of patients suffering from chronic pain. It currently has negative earnings. The Firm has developed and commercialized the Senza spinal cord stimulation system, an evidence neuromodulation platform for the treatment of chronic pain.

Ignyta, Inc. is a biotechnology company. The company has market cap of $552.85 million. The Firm is focused on precision medicine in oncology. It currently has negative earnings. The Firm is pursuing an integrated therapeutic and companion diagnostic (Dx) strategy for treating cancer patients.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com